Elanco begins phased U.S. launch of Befrena for canine dermatitis

Elanco has begun a phased U.S. launch of Befrena (tirnovetmab), a new anti-IL-31 monoclonal antibody injection for dogs with allergic and atopic dermatitis, expanding its dermatology portfolio as seasonal itch cases rise. The product was approved by the USDA in late December 2025 and is now being used by select clinics through an Early Experience Program, with Elanco positioning it alongside Zenrelia as part of a broader push into canine dermatology. Elanco says Befrena starts controlling itch within 24 hours and is recommended at 6- to 8-week dosing intervals. (elanco.com)

Why it matters: For veterinary professionals, Befrena adds another biologic option in a crowded but still high-demand canine dermatology market, where case volume is driven by chronic disease, seasonality, and delayed presentation by pet parents. The launch is also notable because Befrena is regulated as a veterinary biologic through USDA APHIS rather than FDA, while Elanco’s oral dermatology product Zenrelia is FDA-approved, giving clinics another mechanism-based choice when building long-term itch-management plans. (aphis.usda.gov)

What to watch: Watch for broader commercial rollout, real-world clinic uptake, and whether dermatologists and general practitioners see Befrena carve out share against existing anti-itch injectables over the rest of 2026. (prnewswire.com)